Journal of Pharmacokinetics & Experimental Therapeutics

Reker, J Pharmacokinet Exp Ther 2023, 7:5

Review Article Open Access

Introduction

e eld of drug discovery has witnessed a remarkable transformation in recent years, thanks to the integration of cutting-edge technologies and data-driven approaches. Among these transformative technologies, active machine learning has emerged as a powerful tool with the potential to expedite and enhance the drug development process. Active machine learning, a subset of arti cial intelligence, is revolutionizing how pharmaceutical researchers identify and design new therapeutic compounds. It empowers scientists to make more informed decisions by intelligently selecting experiments, optimizing resources, [(n)4(e)-872e12(f a)0(t)11wgbsetio ex inwith vast datasets, complex molecular interactions, and the pressing need to address a wide range of diseases. Traditional drug discovery methodologies, while e ective, o en prove costly and time-consuming. Active machine learning, through its iterative learning and decision-making processes, o ers a dynamic approach to tackle these challenges head-on. By prioritizing experiments, selecting promising molecular candidates, and continually improving predictive models, active machine learning enhances the e ciency and e ectiveness of drug discovery e orts. is introduction sets the stage for our exploration of active machine learning in drug discovery, focusing on the practical considerations that underpin its implementation [2]. We will delve into

WRQ0DNVFHHRFXWQ7KDVHVWQ EHLWXDWHNQQ

from preceding energetic gaining knowledge of research to spotlight the challenges and possibilities of making use of adaptive desktop mastering to drug discovery. Speciýcally, concerns related to implementation, infrastructural

high-throughput screening. Some small-scale comparisons have proven that lively gaining knowledge of may allow an extra ne-tuned strategy that adjusts to prior statistics and can be programmed to greater swi ly domestic in on promising answer [7,8].

Conclusion

In conclusion, active machine learning has emerged as a powerful ally in the realm of drug discovery, o ering novel solutions to the formidable challenges that have long characterized this eld. By harnessing the potential of computational intelligence, researchers and pharmaceutical companies have the opportunity to not only expedite the discovery of innovative therapeutic agents but also to allocate resources more e ectively, ultimately reducing the cost and time associated with drug development. e need for high-quality, diverse data, the interpretability of machine learning models, and ethical concerns regarding data privacy are just a few of the issues that must be navigated. With an interdisciplinary approach and ongoing collaboration between computational experts and life science researchers, we can expect active machine learning to play an increasingly pivotal role in the transformation of drug discovery, ultimately improving the lives of countless individuals worldwide.

Con ict of Interest

None

Acknowledgment

None

References

1. Adibhatla RM, Hatcher JF, Dempsey RJ (2002) Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 80: 12-23.
2. Schäbitz WR, Weber J, Takano K, Sandage BW (1996) The e ects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 138: 21-25.
3. Hazama T, Hasegawa T, Ueda S, Sakuma A (1980) Evaluation of the e ect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci 11: 211-225.
4. Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, et al. (2012) Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380: 349-357.
5. Marei HE, Hasan A, Rizzi R, Althani A, Aýý N, et al. (2018) Potential of stem cell-based therapy for ischemic stroke. Front Neurol 9: 34.
6. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, et al. (2016) Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. Int J Stroke 11: 459-484.
7. Lee TD, Swanson LR, Hall AL (1991) What is repeated in a repetition? E ects of practice conditions on motor skill acquisition. Phys Ther 71: 150-156.
8. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, et al. (2016) Guidelines for adult stroke rehabilitation and recovery: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 47: e98-e169.